Healthcare costs and resource use in advanced breast cancer at the end of life: a register study
DOI:
https://doi.org/10.2340/1651-226X.2026.44970Abstract
Background and purpose: Advanced breast cancer (ABC) involves substantial end-of-life (EOL) healthcare use and costs. Understanding cost drivers can inform care delivery and resource allocation.
Patient/material and methods: We conducted a retrospective, population-based study of individuals (n = 1,437) who died with breast cancer in the Stockholm Region (2015–2023). Healthcare utilization and costs during the last 12 months of life were obtained from the Stockholm Regional Healthcare Data Repository (VAL) and estimated using the Region Stockholm cost model. Variables included age, sex, socioeconomic status (Mosaic), Charlson Comorbidity Index, Hospital Frailty Risk Score (HFRS), systemic therapy, and place of death. Descriptive statistics and generalized linear models assessed cost associations.
Results: Total costs rose toward EOL, increasing 140% in the final 3 months versus the prior quarter. Hospitalizations and specialized palliative care drove costs, while outpatient visits declined. Younger age (18–69 years), high frailty (HFRS > 15), and systemic therapy were independently associated with higher costs. Hospital death was associated with lower expenditures than dying elsewhere (rate ratio [RR]: 0.84, 95% confidence interval [CI]: 0.78–0.91). The top 5% of cost users were mainly younger, frail patients receiving systemic therapy.
Interpretation: ABC-related costs escalate in the final year of life, driven by hospitalizations, palliative care, and systemic therapies. Younger, frailer patients incur higher costs, while those dying in hospital settings are associated with lower costs. Early palliative integration and frailty-based risk stratification were associated with distinct patterns of healthcare utilization and costs toward the EOL.
Downloads
References
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.
https://doi.org/10.3322/caac.21834 DOI: https://doi.org/10.3322/caac.21834
Hofmarcher T, Lindgren P, Wilking N, Jönsson B. The cost of cancer in Europe 2018. Eur J Cancer (Oxford, England: 1990). 2020;129:41–9.
https://doi.org/10.1016/j.ejca.2020.01.011 DOI: https://doi.org/10.1016/j.ejca.2020.01.011
Sun L, Legood R, Dos-Santos-Silva I, Gaiha SM, Sadique Z. Global treatment costs of breast cancer by stage: a systematic review. PLoS One. 2018;13(11):e0207993.
https://doi.org/10.1371/journal.pone.0207993 DOI: https://doi.org/10.1371/journal.pone.0207993
Bramley T, Antao V, Lunacsek O, Hennenfent K, Masaquel A. The economic burden of end-of-life care in metastatic breast cancer. J Med Econ. 2016;19(11):1075–80.
https://doi.org/10.1080/13696998.2016.1197130 DOI: https://doi.org/10.1080/13696998.2016.1197130
Khan SA, Hernandez-Villafuerte K, Hernandez D, Schlander M. Estimation of the stage-wise costs of breast cancer in Germany using a modeling approach. Front Public Health. 2022;10:946544.
https://doi.org/10.3389/fpubh.2022.946544 DOI: https://doi.org/10.3389/fpubh.2022.946544
Bentur N, Resnizky S, Balicer R, Eilat-Tsanani T. Utilization and cost of services in the last 6 months of life of patients with cancer – with and without home hospice care. Am J Hosp Palliat Care. 2014;31(7):723–5.
https://doi.org/10.1177/1049909113499604 DOI: https://doi.org/10.1177/1049909113499604
Khaki AR, Xu Y, Cheung WY, Li L, Fedorenko C, Grivas P, et al. Comparison of health care utilization at the end of life among patients with cancer in Alberta, Canada, Versus Washington State. JCO Oncol Pract. 2020;16(12):e1543–52.
https://doi.org/10.1200/OP.20.00217 DOI: https://doi.org/10.1200/OP.20.00217
Glisch C, Hagiwara Y, Gilbertson-White S, Gao Y, Lyckholm L. Immune checkpoint inhibitor use near the end of life is associated with poor performance status, lower hospice enrollment, and dying in the hospital. Am J Hosp Palliat Care. 2020;37(3):179–84.
https://doi.org/10.1177/1049909119862785 DOI: https://doi.org/10.1177/1049909119862785
Crawford GB, Dzierżanowski T, Hauser K, Larkin P, Luque-Blanco AI, Murphy I, et al. Care of the adult cancer patient at the end of life: ESMO clinical practice guidelines. ESMO Open. 2021;6(4):100225.
https://doi.org/10.1016/j.esmoop.2021.100225 DOI: https://doi.org/10.1016/j.esmoop.2021.100225
Langton JM, Reeve R, Srasuebkul P, Haas M, Viney R, Currow D, et al. Health service use and costs in the last 6 months of life in elderly decedents with a history of cancer: a comprehensive analysis from a health payer perspective. Br J Cancer. 2016;114(11):1293–302.
https://doi.org/10.1038/bjc.2016.75 DOI: https://doi.org/10.1038/bjc.2016.75
O’Connor TL, Ngamphaiboon N, Groman A, Luczkiewicz DL, Kuszczak SM, Grant PC, et al. Hospice utilization and end-of-life care in metastatic breast cancer patients at a comprehensive cancer center. J Palliat Med. 2015;18(1):50–5.
https://doi.org/10.1089/jpm.2014.0238 DOI: https://doi.org/10.1089/jpm.2014.0238
Von Bahr L, Strang P, Schultz T, Fürst P. Receipt of specialized palliative care and health care utilization at the end of life in hematological cancer patients – the Stockholm experience. Acta Oncol (Stockholm, Sweden). 2025;64:234–40.
https://doi.org/10.2340/1651-226X.2025.42189 DOI: https://doi.org/10.2340/1651-226X.2025.42189
Strang P, Petzold M, Björkhem-Bergman L, Schultz T. Differences in health care expenditures by cancer patients during their last year of life: a registry-based study. Curr Oncol (Toronto, Ont). 2024;31(10):6205–17.
https://doi.org/10.3390/curroncol31100462 DOI: https://doi.org/10.3390/curroncol31100462
Boo Hammas K, Jacobsen J, Selberg R, Mahajan S, Klintman J. Gender differences in palliative care needs among Swedish cancer patients prior to specialist palliative care referral. Acta Oncol (Stockholm, Sweden). 2025;64:672–6.
https://doi.org/10.2340/1651-226X.2025.43308 DOI: https://doi.org/10.2340/1651-226X.2025.43308
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344–9.
https://doi.org/10.1016/j.jclinepi.2007.11.008 DOI: https://doi.org/10.1016/j.jclinepi.2007.11.008
Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4(10):e297.
https://doi.org/10.1371/journal.pmed.0040297 DOI: https://doi.org/10.1371/journal.pmed.0040297
Eckart A, Hauser SI, Haubitz S, Struja T, Kutz A, Koch D, et al. Validation of the hospital frailty risk score in a tertiary care hospital in Switzerland: results of a prospective, observational study. BMJ Open. 2019;9(1):e026923.
https://doi.org/10.1136/bmjopen-2018-026923 DOI: https://doi.org/10.1136/bmjopen-2018-026923
Gilbert T, Neuburger J, Kraindler J, Keeble E, Smith P, Ariti C, et al. Development and validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using electronic hospital records: an observational study. Lancet (London, England). 2018;391(10132):1775–82.
https://doi.org/10.1016/S0140-6736(18)30668-8 DOI: https://doi.org/10.1016/S0140-6736(18)30668-8
Fridegren J, Björkhem-Bergman L, Schultz T, Strang P. Ascites as a predictive factor in malignancies in the last year of life-comparison between different cancer types. J Palliat Med. 2025;28(1):35–41.
https://doi.org/10.1089/jpm.2024.0140 DOI: https://doi.org/10.1089/jpm.2024.0140
Bergqvist J, Hedman C, Schultz T, Strang P. Equal receipt of specialized palliative care in breast and prostate cancer: a register study. Support Care Cancer. 2022;30(9):7721–30. DOI: https://doi.org/10.1007/s00520-022-07150-y
Charlson ME, Carrozzino D, Guidi J, Patierno C. Charlson Comorbidity Index: a critical review of clinimetric properties. Psychother Psychosom. 2022;91(1):8–35.
https://doi.org/10.1159/000521288 DOI: https://doi.org/10.1159/000521288
Strang P, Schultz T. The impact of frailty on palliative care receipt, emergency room visits and hospital deaths in cancer patients: a registry-based study. Curr Oncol. 2023;30(7):6623–33. DOI: https://doi.org/10.3390/curroncol30070486
Salaj D, Schultz T, Strang P. Medical costs of Swedish nursing home residents at the end of life: a retrospective observational registry study. BMC Geriatr. 2024;24(1):580.
https://doi.org/10.1186/s12877-024-05043-9 DOI: https://doi.org/10.1186/s12877-024-05043-9
Foster TS, Miller JD, Boye ME, Blieden MB, Gidwani R, Russell MW. The economic burden of metastatic breast cancer: a systematic review of literature from developed countries. Cancer Treat Rev. 2011;37(6):405–15. DOI: https://doi.org/10.1016/j.ctrv.2010.12.008
Singh J, Stensvold A, Turzer M, Grov EK. Anticancer therapy at end-of-life: a retrospective cohort study. Acta Oncol (Stockholm, Sweden). 2024;63:313–21.
https://doi.org/10.2340/1651-226X.2024.22139 DOI: https://doi.org/10.2340/1651-226X.2024.22139
Schneider PP, Pouwels X, Passos VL, Ramaekers BLT, Geurts SME, Ibragimova KIE, et al. Variability of cost trajectories over the last year of life in patients with advanced breast cancer in the Netherlands. PLoS one. 2020;15(4):e0230909. DOI: https://doi.org/10.1371/journal.pone.0230909
Bugge C, Saether EM, Kristiansen IS. Men receive more end-of-life cancer hospital treatment than women: fact or fiction? Acta Oncol (Stockholm, Sweden). 2021;60(8):984–91.
https://doi.org/10.1080/0284186X.2021.1917000 DOI: https://doi.org/10.1080/0284186X.2021.1917000
Trogdon JG, Baggett CD, Gogate A, Reeder-Hayes KE, Rotter J, Zhou X, et al. Medical costs associated with metastatic breast cancer in younger, midlife, and older women. Breast Cancer Res Treat. 2020;181(3):653–65. DOI: https://doi.org/10.1007/s10549-020-05654-x
de Oliveira C, Pataky R, Bremner KE, Rangrej J, Chan KK, Cheung WY, et al. Phase-specific and lifetime costs of cancer care in Ontario, Canada. BMC Cancer. 2016;16(1):809.
https://doi.org/10.1186/s12885-016-2835-7 DOI: https://doi.org/10.1186/s12885-016-2835-7
Gogate A, Wheeler SB, Reeder-Hayes KE, Ekwueme DU, Fairley TL, Drier S, et al. Projecting the prevalence and costs of metastatic breast cancer from 2015 through 2030. JNCI Cancer Spectrum. 2021;5(4) :pkab063.
https://doi.org/10.1093/jncics/pkab063 DOI: https://doi.org/10.1093/jncics/pkab063
Yoon SJ, Kim EJ, Seo HJ, Oh IH. The Association between Charlson Comorbidity Index and the medical care cost of cancer: a retrospective study. Biomed Res Int. 2015;2015:259341. DOI: https://doi.org/10.1155/2015/259341
Diernberger K, Luta X, Bowden J, Fallon M, Droney J, Lemmon E, et al. Healthcare use and costs in the last year of life: a national population data linkage study. BMJ Support Palliat Care. 2024;14(e1):e885-e892.
https://doi.org/10.1136/bmjspcare-2020-002708 DOI: https://doi.org/10.1136/bmjspcare-2020-002708
Diernberger K, Luta X, Bowden J, Droney J, Lemmon E, Tramonti G, et al. Variation in hospital cost trajectories at the end of life by age, multimorbidity and cancer type. Int J Popul Data Sci. 2023;8(1):1768. DOI: https://doi.org/10.23889/ijpds.v8i1.1768
Jauhari Y, Gannon MR, Dodwell D, Horgan K, Tsang C, Clements K, et al. Addressing frailty in patients with breast cancer: a review of the literature. Eur J Surg Oncol. 2020;46(1):24–32.
https://doi.org/10.1016/j.ejso.2019.08.011 DOI: https://doi.org/10.1016/j.ejso.2019.08.011
Tsai HH, Yu JC, Hsu HM, Chu CH, Hong ZJ, Feng AC, et al. The impact of frailty on breast cancer outcomes: evidence from analysis of the Nationwide Inpatient Sample, 2005–2018. Am J Cancer Res. 2022;12(12):5589–98.
Chastek B, Harley C, Kallich J, Newcomer L, Paoli CJ, Teitelbaum AH. Health care costs for patients with cancer at the end of life. J Oncol Pract. 2012;8(6):75s–80s.
https://doi.org/10.1200/JOP.2011.000469 DOI: https://doi.org/10.1200/JOP.2011.000469
Balasubramanian I, Malhotra C. Why is end-of-life inpatient cost high among cancer patients? A prospective cohort study. Cancer Med. 2024;13(4):e7057. DOI: https://doi.org/10.1002/cam4.7057
Cheung MC, Earle CC, Rangrej J, Ho TH, Liu N, Barbera L, et al. Impact of aggressive management and palliative care on cancer costs in the final month of life. Cancer. 2015;121(18): DOI: https://doi.org/10.1002/cncr.29485
3307–15.
de Oliveira C, Cheng J, Chan K, Earle CC, Krahn M, Mittmann N. High-cost patients and preventable spending: a population-based study. J Natl Compr Canc Netw. 2020;18(1):23–31.
https://doi.org/10.6004/jnccn.2019.7342 DOI: https://doi.org/10.6004/jnccn.2019.7342
Meropol NJ, Schulman KA. Cost of cancer care: issues and implications. J Clin Oncol. 2007;25(2):180–6. DOI: https://doi.org/10.1200/JCO.2006.09.6081
de Oliveira C, Bremner KE, Pataky R, Gunraj N, Chan K, Peacock S, et al. Understanding the costs of cancer care before and after diagnosis for the 21 most common cancers in Ontario: a population-based descriptive study. CMAJ Open. 2013;1(1):E1–8.
https://doi.org/10.9778/cmajo.20120013 DOI: https://doi.org/10.9778/cmajo.20120013
Sarfati D, Koczwara B, Jackson C. The impact of comorbidity on cancer and its treatment. CA Cancer J Clin. 2016;66(4):337–50.
https://doi.org/10.3322/caac.21342 DOI: https://doi.org/10.3322/caac.21342
Tinetti ME, Fried TR, Boyd CM. Designing health care for the most common chronic condition – multimorbidity. JAMA. 2012;307(23):2493–4.
https://doi.org/10.1001/jama.2012.5265 DOI: https://doi.org/10.1001/jama.2012.5265
Blagden SP, Charman SC, Sharples LD, Magee LR, Gilligan D. Performance status score: do patients and their oncologists agree? Br J Cancer. 2003;89(6):1022–7. DOI: https://doi.org/10.1038/sj.bjc.6601231
Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733–42.
https://doi.org/10.1056/NEJMoa1000678 DOI: https://doi.org/10.1056/NEJMoa1000678
Ferrell BR, Temel JS, Temin S, Smith TJ. Integration of palliative care into standard oncology care: ASCO clinical practice guideline update summary. J Oncol Pract. 2017;13(2):119–21.
https://doi.org/10.1200/JOP.2016.017897 DOI: https://doi.org/10.1200/JOP.2016.017897
Kaasa S, Loge JH, Aapro M, Albreht T, Anderson R, Bruera E, et al. Integration of oncology and palliative care: a Lancet Oncology Commission. Lancet Oncol. 2018;19(11):e588–653.
https://doi.org/10.1016/S1470-2045(18)30415-7 DOI: https://doi.org/10.1016/S1470-2045(18)30415-7
Sahlen KG, Boman K, Brännström M. A cost-effectiveness study of person-centered integrated heart failure and palliative home care: based on a randomized controlled trial. Palliat Med. 2016;30(3):296–302.
https://doi.org/10.1177/0269216315618544 DOI: https://doi.org/10.1177/0269216315618544
Adsersen M, Hansen MB, Neergaard MA, Sjøgren P, Guldin MB, Groenvold M. The first decade of the Danish Palliative Care Database: improvements and ongoing challenges in the quality and use of specialised palliative care. Acta Oncol (Stockholm, Sweden). 2024;63:259–66.
https://doi.org/10.2340/1651-226X.2024.28515 DOI: https://doi.org/10.2340/1651-226X.2024.28515
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Giovanni Galvis Rojas, Peter Strang, Torbjörn Schultz , Lars-Åke Levin
This work is licensed under a Creative Commons Attribution 4.0 International License.
